The TRITON clinical trial programme: Evaluation of the PARP inhibitor rucaparib in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)

被引：0
|
作者：
Chowdhury, S. [1 ,2 ]
Abida, W. [3 ]
Arranz Arija, J. [4 ]
Daugaard, G. [5 ]
Fizazi, K. [6 ]
Gez, E. [7 ]
Heidenreich, A. [8 ]
Joly Lobbedez, F. [9 ]
McDermott, R. [10 ]
Merseburger, A. S. [11 ]
Piulats Rodriguez, J. M. [12 ]
Sautois, B. [13 ]
Sridhar, S. [14 ]
Sternberg, C. N. [15 ]
Watkins, S. [16 ]
Simmons, A. [17 ]
Shetty, S. [18 ]
Golsorkhi, A. [19 ]
Ryan, C. J.
Scher, H. [3 ,20 ]
机构：
[1] Guys Hosp, Urol Canc, London, England
[2] Sarah Cannon Res Inst, London, England
[3] Mem Sloan Kettering Canc Ctr, Genitourinary Oncol, 1275 York Ave, New York, NY 10021 USA
[4] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain
[5] Copenhagen Univ Hosp, Rigshospitalet, Oncol, Copenhagen, Denmark
[6] Univ Paris, Grp Urogenitol, Villejuif, France
[7] Sourasky Med Ctr, Dept Oncol, Tel Aviv, Israel
[8] Univ Klinikum Koln, Klin Urol, Cologne, Germany
[9] Ctr Francois Baclesse, Med Oncol, Caen, France
[10] Tallaght & St Vincents Univ Hosp & Canc Trials Ir, Genitourinary Oncol, Dublin, Ireland
[11] Lubeck Univ Hosp, Urol Oncol, Lubeck, Germany
[12] Inst Catalan Oncol, Med Oncol, Barcelona, Spain
[13] Univ Hosp Liege, Med Oncol, Liege, Belgium
[14] Princess Margaret Hosp, Med Oncol, Toronto, ON, Canada
[15] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy
[16] Clovis Oncol Inc, Clin Sci, Boulder, CO USA
[17] Clovis Oncol Inc, Boulder, CO USA
[18] Clovis Oncol Inc, Clin Operat, Boulder, CO USA
[19] Clovis Oncol Inc, Clin Dev, Boulder, CO USA
[20] UCSF Helen Diller Family Comprehens Canc Ctr, Genitourinary Med Oncol, San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
836TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
    Cora, N. S.
    Sergio, B.
    Ugo, D. G.
    Giuseppe, P.
    Simon, C.
    Wassim, A.
    Angel, A. A. Jose
    Gedske, D.
    Karim, F.
    Eliahu, G.
    Axel, H.
    Florence, J.
    Ray, M.
    Axel, S. M.
    Maria, P. Josep
    Brieuc, S.
    Srikala, S.
    Tony, G.
    Charles, J. R.
    Howard, I. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [2] The Triton Clinical Trial Programme: Evaluation of the Parp Inhibitor Rucaparib in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated With Homologous Recombination Deficiency (HRD)
    Krieger, Laurence
    Shapiro, Jeremy
    Byard, Ian
    Campbell, David
    Clay, Timothy
    Ganju, Vinod
    Watkins, Simon
    Simmons, Andy
    Go, Jowell
    Shetty, Sanjay
    Golsorkhi, Tony
    Abida, Wassim
    Ryan, Charles J.
    Scher, Howard I.
    Chowdhury, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 164 - 164
  • [3] TRIAL OF RUCAPARIB IN PROSTATE INDICATIONS 2 (TRITON2): AN INTERNATIONAL, MULTICENTRE, OPEN-LABEL PHASE 2 STUDY OF THE PARP INHIBITOR RUCAPARIB IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
    Shapiro, Jeremy
    Voskoboynik, Mark
    Krieger, Laurence
    Byard, Ian
    Clay, Timothy
    Ganju, Vinod
    Abida, Wassim
    Chowdhury, Simon
    Watkins, Simon
    Despain, Darrin
    Simmons, Andy
    Go, Jowell
    Golsorkhi, Tony
    Scher, Howard I.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 61 - 61
  • [4] TRITON2: An International, Multicentre, Open-Label Phase 2 Study of the PARP Inhibitor Rucaparib in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associated with Homologous Recombination Deficiency (HRD)
    Heidenreich, A.
    Carl, S.
    Feyerabend, S.
    Gleissner, J.
    Gruellich, C.
    Heinrich, B.
    Merseburger, A.
    Miller, K.
    Stenzl, A.
    Steuber, T.
    Wirth, M.
    Watkins, S.
    Simmons, A.
    Go, J.
    Golsorkhi, T.
    Abida, W.
    Scher, H. I.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 75 - 75
  • [5] TRITON2: An international, multicenter, open-label, phase II study of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
    Abida, Wassim
    Bryce, Alan Haruo
    Balar, Arjun Vasant
    Chatta, Gurkamal S.
    Dawson, Nancy Ann
    Guancial, Elizabeth A.
    Hussain, Arif
    Jha, Gautam Gopalji
    Lipsitz, David Uri
    Patnaik, Akash
    Petrylak, Daniel Peter
    Ryan, Charles J.
    Stanton, Thomas S.
    Vogelzang, Nicholas J.
    Zhang, Jingsong
    Simmons, Andrew
    Go, Jowell
    Golsorkhi, Tony
    Chowdhury, Simon
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician's choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
    Ryan, Charles J.
    Abida, Wassim
    Bryce, Alan Haruo
    Balar, Arjun Vasant
    Dumbadze, Igor
    Given, Robert W.
    Morris, David
    Petrylak, Daniel Peter
    Redfern, Charles H.
    Scher, Howard I.
    Watkins, Simon Paul
    Simmons, Andrew
    Passler, Luke
    Golsorkhi, Tony
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [7] Trial of rucaparib in prostate indications 3 (TRITON3): An international, multicenter, randomized, open-label phase 3 study of rucaparib vs physician's choice of therapy for patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD).
    Ryan, Charles J.
    Watkins, Simon Paul
    Despain, Darrin
    Karlovich, Chris Alan
    Simmons, Andrew
    Golsorkhi, Anthony A.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [8] TRITON3: An International, Randomised, Open-Label Phase 3 Study of the PARP Inhibitor Rucaparib vs Physician's Choice of Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Associate with Homologous Recombination Deficiency (HRD)
    Merseburger, A.
    Carl, S.
    Feyerabend, S.
    Gleissner, J.
    Grimm, M. -O.
    Gruellich, C.
    Heidenreich, A.
    Heinrich, B.
    Miller, K.
    Stenzl, A.
    Steuber, T.
    Wirth, M.
    Watkins, S.
    Simmons, A.
    Passler, L.
    Shetty, S.
    Golsorkhi, T.
    Ryan, C.
    Chowdhury, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 74 - 74
  • [9] Pamiparib, an investigational PARP inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) and a circulating tumor cell (CTC) homologous recombination deficiency (HRD) phenotype or BRCA defects: A trial in progress.
    Chowdhury, Simon
    Mateo, Joaquin
    Gross, Mitchell
    Armstrong, Andrew J.
    Cruz-Correa, Marcia
    Piulats, Josep M.
    Blay, Jean-Yves
    Li, Miao
    Rivas, Delcia
    Quintero, Luis
    Castro, Henry
    Nkobena, Andong
    Raponi, Mitch
    Pelham, Robert
    Landers, Mark
    Montgomery, Robert B.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [10] TRIAL OF RUCAPARIB IN PROSTATE INDICATIONS 3 (TRITON3): AN INTERNATIONAL, MULTICENTRE, RANDOMISED, OPEN-LABEL PHASE 3 STUDY OF RUCAPARIB VS PHYSICIAN'S CHOICE OF THERAPY FOR PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) ASSOCIATED WITH HOMOLOGOUS RECOMBINATION DEFICIENCY (HRD)
    Krieger, Laurence
    Byard, Ian
    Clay, Timothy
    Ganju, Vinod
    Ryan, Charles J.
    Watkins, Simon
    Despain, Darrin
    Simmons, Andy
    Miyamoto, Emiko
    Golsorkhi, Tony
    Chowdhury, Simon
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 : 50 - 50
12345